


# Stabilis



## Alfentanil hydrochloride



Noms commerciaux

Alfenta	Etats Unis d'Amérique, Iran, Pérou
Alfentanil	Allemagne, Canada, Chili, Colombie, Etats Unis d'Amérique, Grande Bretagne, Iran
Alfiject	Iran
Limifen	Espagne
Rapifen	Allemagne, Arabie Saoudite, Australie, Autriche, Belgique, Chili, Danemark, Finlande, France, Grande Bretagne, Grèce, Hongrie, Irlande, Luxembourg, Malaisie, Norvège, Nouvelle Zélande, Pays bas, Pologne, Portugal, Suède, Suisse, Tunisie



### Stabilité en mélange

PP	Stabilité	Concentration	Température	Compatibilité	Substance	Temps	Stabilité	Code
PP	▲	55 µg/ml	2-8°C	☀️	Morphine sulfate : 0,8 mg/ml	180	☾	2086
PP	▲	55 µg/ml	22°C	☀️	Morphine sulfate : 0,8 mg/ml	180	☾	2086
PP	▲	167 µg/ml	23°C	☀️	Ondansetron hydrochloride : 1,33 mg/ml	24	☑️	815
PP	▲	167 µg/ml	4°C	☀️	Ondansetron hydrochloride : 1,33 mg/ml	24	☑️	815




### Compatibilités

Stabilité	Compatibilité	Concentration	Substance	Stabilité	Code
↙	✗	Alfentanil hydrochloride : 500 µg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml	☀️	♦️	921
	☑️	Alfentanil hydrochloride : 125 µg/ml Bivalirudin : 5 mg/ml	☀️	♦️	1713
	☑️	Alfentanil hydrochloride : 500 µg/ml Cefazolin sodium : 20 mg/ml	☀️		3380
	☑️	Alfentanil hydrochloride : 500 µg/ml Cefuroxime sodium : 30 mg/ml	☀️		3380
	☑️	Alfentanil hydrochloride Cisatracurium besylate	☀️		3601

	Alfentanil hydrochloride : 125 µg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Alfentanil hydrochloride : 50 µg/ml Dexmedetomidine : 4 µg/ml		1712
	Alfentanil hydrochloride : 500 µg/ml Etomidate : 2 mg/ml		319
	Alfentanil hydrochloride : 500 µg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Alfentanil hydrochloride : 125 µg/ml Hetastarch : 60 mg/ml		1721
			1625
	Alfentanil hydrochloride : 500 µg/ml Linezolid : 2 mg/ml		1925
	Alfentanil hydrochloride : 55 µg/ml Morphine sulfate : 0,8 mg/ml		2086
	Alfentanil hydrochloride : 167 µg/ml Ondansetron hydrochloride : 1.33 mg/ml		815
			3504
			1861
	Alfentanil hydrochloride : 10 & 25 µg/ml Propofol : 10 mg/ml		3502
	Alfentanil hydrochloride : 500 µg/ml Propofol : 10 mg/ml		300
	Alfentanil hydrochloride : 500 µg/ml Propofol : 2 mg/ml		319
			660
	Alfentanil hydrochloride : 125 µg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
	Alfentanil hydrochloride : 500 µg/ml Thiopental sodium : 25 mg/ml		319



## Voie d'administration








































## Bibliographie

	Type	Source
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1861	Revue	Levadoux E, Sautou V, Bazin JE, Schoeffler P, Chopineau J. Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture. Int J Pharm 1996 ; 127: 255-259.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2086	Revue	Sharley NA, Burgess NG. Stability and compatibility of alfentanil hydrochloride and morphine sulfate in polypropylene syringes. J Pharm Pract and Res 2003 ; 33: 279-281.
3380	Revue	Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Pirtramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427.
3502	Laboratoire	Propofol (Diprivan®) - Summary of Products Characteristics Astra Zeneca 2012
3504	Laboratoire	Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012
3601	Laboratoire	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012



# Dictionnaire

 Antalgique	 Injectable
 Noms commerciaux	 Stabilité en mélange
 Contenant	 Solvant
 Concentration	 Température
 Conservation	 Molécule
 Durée de stabilité	 Bibliographie
 Polypropylène	 Chlorure de sodium 0,9%
 A l'abri de la lumière	 Jour
 Lumière	 Heure
 Compatibilités	 Précipitation immédiate
 Incompatible	 Glucose 5%
 Compatible	 Aucun
 Solvant spécifique	 Incompatibilité non précisée
 Instabilité de l'émulsion en 24 heures	 Eau pour préparation injectable
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Perfusion continue
 Intramusculaire	 Sous cutanée
 Perfusion SC continue	 Bibliographie
 Dictionnaire	